Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 22 for “"PIK3CA"”.
-
Investigation of genetic PIK3CA activation in genome-edited human pluripotent stem cells
Mosaic, activating mutations in PIK3CA, the gene encoding the catalytic p110α subunit of class IA phosphatidylinositol 3-kinase (PI3K), are the cause of rare, developmental growth disorders collectively known as PIK3CA-Related Overgrowth Spectrum (PROS). Given the pressing need for targeted therapy …
-
Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer
… and mechanisms of resistance. We found that PIK3CA mutation status as well as tumor subtype (luminal-like or basal-like) play cooperative role in driving treatment response, where PIK3CA E542K mutation in basal-like tumors is associated with resistance to PI3K inhibition. Resistance is driven …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… Hospital Tokuda – Sofia). The prevalence of the PIK3CA mutation and its relationship to certain clinicopathological characteristics of the patients and their response to first-line therapy were investigated. The data analysis was retrospective. All patients provided histological samples for …
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
… HER2-NEGATIVE BREAST CANCER WITH <em>PIK3CA/AKT1</em> MUTATIONS</strong></p> <p>Maryam Shariati, M.S. Advisory Professor: Funda Meric-Bernstam, M.D.</p> <p>Molecular alterations in the phosphatidylinositol 3‑kinase (PI3K)/ serine/threonine protein kinase B (AKT) signaling pathway occur …
-
Modulation of Pi3K-Akt Pathway In Colorectal Cancer
… through PTEN loss (PTEN<sup>loss</sup>) and <em>PIK3CA</em> mutations (<em>PIK3CA</em><sup>mut</sup>). Allosteric AKT inhibition with MK2206 monotherapy has been ineffective in CRC patients. We investigated the impact of MK2206 on pharmacodynamic (PD) markers and signaling pathways using reverse …
-
Basis For Targeting Met Activation Mediated Resistance to Pi3K Inhibition In Breast Cancer
… tumors, and showed that <em>MET</em> and <em>PIK3CA</em> are frequently co-amplified, and a high copy number of either gene is associated with poorer prognostic features and the triple negative disease.(<a href="http://digitalcommons.library.tmc.edu/cgi/ir_submit.cgi#_ENREF_2" …
-
Genetic and Epigenetic Characterisation of Breast Tumours
… In Paper I, we studied genetic alterations of PIK3CA and PTEN as well as PTEN protein expression. We found frequent alterations in the two PI3K pathway components PIK3CA (26%) and PTEN (31%). The alterations in PIK3CA were associated with oestrogen receptor (ER) positivity, whereas PTEN …
-
Πραγματικά δεδομένα σχετικά με τις μεταλλάξεις Pi3k σε ασθενείς με μεταστατικό HR(+), HER2(-) καρκίνο του μαστού: ανασκόπηση της βιβλιογραφίας από ένα μόνο κέντρο σχετικά με την αποτελεσματικότητα του inavolisib/capivasertib / Real world data regarding Pi3k mutations in metastatic HR(+), HER2(-) BC patients: a single center experience review of literature regarding the efficacy of inavolisib/capivasertib
Το μονοπάτι σηματοδότησης PIK3CA/AKT1/PTEN διαδραματίζει καθοριστικό ρόλο στον κυτταρικό πολλαπλασιασμό, τον μεταβολισμό, την επιβίωση και την απόπτωση. Σε ασθενείς με HR+/HER2- καρκίνο του μαστού αποτελεί το συχνότερα απορρυθμισμένο σηματοδοτικό μονοπάτι και έχει συσχετιστεί με την ανάπτυξη …
-
EBV-Associated Gastric Cancer: From Initial Infection to Unique Therapeutic Approaches
… EBVaGCs display an 80% rate of activating PIK3CA mutation and are also the most hypermethylated of any tumor type, displaying what is known as a CpG island hypermethylator phenotype (CIMP). EBV infection of B cells can be easily modeled in vitro using primary B cells and lymphoblastoid cell …
-
Host somatic variation between women living with HIV with cervical intraepitheial lesions (CIN3) and their HIV negative counterparts
… in the four commonly mutated genes (TP53, PIK3CA, PTEN, and EGFR) were genotyped using Polymerase Chain Reaction and validated using Sanger Sequencing. Missense variant pathogenicity was assessed using SIFT, Polyphen-2, and ClinVar tools. The median age was [37 years (IQR:34-41)] for …
-
Investigating the cellular mechanisms that determine RNMT dependency in breast cancer cells
… was found that activating mutations in the gene PIK3CA, which encodes the p110α catalytic subunit of PI3K, contributes to cellular RNMT dependency. Moreover, inhibition of PI3K signalling in a RNMT depletion sensitive breast cancer cell line reverses the sensitivity. These findings provide the …
-
Defining Determinants of Primary Drug Resistance in Precision Cancer Therapies
… triple-negative breast cancer (TNBC) and (2) PIK3CA mutant gastric cancer. Particularly, in the first context, using a candidate drug screen, we discovered that inhibition of cyclin-dependent kinase (CDK) 12 dramatically sensitizes diverse models of TNBC to EGFR blockade. Instead of …
-
MiR-10a Regulation of Drug Response and Cancer Stem Cell Populations in Non-Small Cell Lung Carcinomas
… of genes, meaning that miR-10a may regulate PIK3CA expression both directly and indirectly. We identified the transcription factor GATA6 as both a target of miR-10a with a predicted miR-10a target site in its 3’UTR and a regulator of PI3K expression, with several conserved binding sites in …
-
Investigating PLEKHS1 adaptor function in PI3K signalling and human cancer biology
… genetic alterations in key pathway genes (e.g., *PIK3CA*, *PTEN*). Despite extensive research, the primary drivers of healthy or oncogenic PI3K signalling *in vivo* are largely unknown and PI3K pathway inhibitors show limited clinical benefit in solid tumours. Identifying upstream regulators of …
-
Multi-Modality Plasma-Based Detection of Minimal Residual Disease in Triple-Negative Breast Cancer
… by 16% of the patients having at least one PIK3CA mutation. Next, I sequenced matched plasma samples collected after surgery to identify ctDNA with the same mutations. I observed that by detecting corresponding ctDNA I was able to predict rapid recurrence, but not distant recurrence. To …
-
Analyse genomischer Aberrationen gastraler Marginalzonen B-Zell-Lymphome vom MALT-Typ
… der Region 3q26.2-27, welche den BCL-6- bzw. den PIK3CA-Genlocus beinhaltet. Auch wurden Amplifikationen des MLL-Genlocus auf 11q23-24 und der Region 18q21 und LOH der Regionen 6q23.3-25.3 und 7q31 gefunden. Beim Vergleich mit den DLBCL stellte sich außerdem heraus, dass Allelverluste auf 6q und …
-
Genetic analysis of Kmt2d loss in tumorigenesis using genetically engineered mouse models
… gene expression. In a novel mutant <em>Pik3ca</em>-drive lung cancer model, <em>Kmt2d</em> loss caused lung squamous carcinoma with full penetrance from multiple cells of origin.</p> <p> Phenotypic results from the GEMMs clearly demonstrate the critical role of <em>Kmt2d</em> loss in …
-
Identification of Tissue and Circulating Biomarkers For Premalignant and Malignant Lesions
… 20 important mutated genes (<em>TP53, KRAS, APC, PIK3CA, SMAD4, FBXW7, CTNNB1, SYNE1, CDC27, CSMD1, NRAS, RYR3, NALCN, LRP1B, FAT4, ATM, TMPRSS13, SOX9, CSMD3, MED12</em>) which constantly served to separate adenomas from adenocarcinomas were discovered.</p> <p>The Second project focused on …
-
Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma
… mutations included TP53 (67%), KRAS (11%), PIK3CA (2%) and SF3B1 (2%). A total of 41 gene variants were identified in either pre- or post-NACT samples; 36 (87.8%) of them had variants in TP53 alone, and 3 (7.4%) in KRAS and 1 (2.4%) each for PIK3CA and SF3B1. Undetectable levels of ctDNA …
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… Similarly, mutations in BRAF, PIK3CA and Although a number of resistance mechanisms to cetuximab treatment have been elucidated (in the context of both acute and acquired resistance), there still remains ~20% of patients that do not exhibit any of these alterations but remain …
Page 1 of 2